ClinicalTrials.gg
CompletedNCT00554099Updated Apr 22, 2013Results posted

Asacol Acute Diverticulitis(DIVA)Study

A Phase 2 interventional study of Mesalamine and Probiotic in Diverticulitis, sponsored by Warner Chilcott. Completed at 36 sites in United States. Open to participants aged 35 Years to 85 Years. Per ClinicalTrials.gov, last updated 2013-04-22.

Sponsored by Warner Chilcott (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
117
Allocation
Randomized
Ages
35 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies in Diverticulitis with a site in United States — 3 open to participants now, 5 under way, none of them phase 3. Diverticulitis · United States.

Enrollment
9th of 20
117 · median 104
Started
2007
with 5 others
Phase 2
2 of 33
1 open now
Registered
9th of 33
by date

Among the 33 studies in Diverticulitis with a site in United States, this one is the 9th largest by enrollment of the 20 interventional ones that give a count, is one of 6 that started in 2007, is one of 2 in phase 2, and was the 9th registered.

Diverticulitis

125 studies on the registry are indexed under Diverticulitis; 22 are open to participants now.

Browse Diverticulitis studies →

Open to participants now

3 of the 33 studies in Diverticulitis with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 16 Diverticulitis studies recruiting now, 10 (63%) set no upper age limit and 1 (6%) stops at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 35 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Diverticulitis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether Asacol® 2.4 g/day (400 mg Mesalamine) is safe and effective in the treatment of diverticulitis.

Read the detailed description

This study is designed to evaluate the safety and efficacy of Asacol® 2.4 g/day in generally healthy, adult patients who have had an attack of acute diverticulitis. The study will evaluate the safety and efficacy of a 12 week treatment with Asacol® followed a 9 month non-treatment observation period in approximately 180 patients with acute diverticulitis.

03

Conditions studied

  • Diverticulitis

Browse trials for

04

Who can participate

Ages eligible
35 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A clinical diagnosis of acute diverticulitis
  • Female patients must be (at least 1 year without spontaneous menses) or surgically sterile or have a negative urine pregnancy test and practice acceptable (e.g., abstinence; oral, intramuscular, or implanted hormonal contraception [at least 3 months prior to enrollment]; 2-barrier methods [e.g., condom, diaphragm, or spermicide]; intrauterine device or verbal report of partner with history of non-reversed vasectomy)
  • Willing and able to participate in the study and provide a signed

Exclusion criteria

Exclusion Criteria:

  • Presence of diverticular complications (e.g., fistula, abscess, obstruction, stenosis);
  • Active or recent history (within 6 months) of a peptic ulcer;
  • Prior history of irritable bowel syndrome (IBS), as determined by the Investigator;
  • History of major abdominal surgery (as determined by the Investigator);
  • History of GI surgery within 3 months of diagnosis of acute diverticulitis;
  • History of immunocompromising disease, (HIV) infection, or acquired immunodeficiency syndrome (AIDS);
  • If female patient, active or recent history of endometriosis or dysmenorrhea;
  • Received a dose of a product that contains, or is metabolized to, mesalamine by any route within 4 weeks before the screening visit;
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
117 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Days 1 thru Days 10 to 14 (Visit 2): daily antibiotic therapy, dietary advice, and 6 placebo tablets (matching mesalamine) once a day. Visit 2 thru Week 12 : 1 placebo capsule (matching probiotic) and 6 placebo tablets (matching mesalamine) daily.

    Drug: Placebo · Other: Dietary Advice · Drug: Antibiotic for Diverticulitis

  • Active comparator
    Mesalamine

    Days 1 thru 10-14 (Visit 2): daily antibiotic therapy, dietary advice and 6 - 400 mg mesalamine tablets once a day. Visit 2 thru Week 12: 1 placebo capsule (matching probiotic) and 6 - 400 mg mesalamine tablets daily.

    Drug: Mesalamine · Other: Dietary Advice · Drug: Antibiotic for Diverticulitis

  • Active comparator
    Mesalamine & Probiotic

    Days 1 thru 10-14 (Visit 2): daily antibiotic therapy, dietary advice and 6 - 400 mg mesalamine tablets once daily. Visit 2 thru Week 12: 1- Bifidobacterium infantis 35624 capsule and 6 - 400 mg mesalamine tablets daily

    Drug: Probiotic · Other: Dietary Advice · Drug: Antibiotic for Diverticulitis

Interventions

  • 6 - 400 mg tablets once daily

  • Once capsule daily Bifidobacterium infantis 35624 added at Visit 2 (Day 10 + 4 days)

    Also known as: Align

  • DrugPlacebo

    6 placebo tablets for first 10 (+4) days followed by once daily placebo tablets.

  • OtherDietary Advice

    Dietary advice

  • DrugAntibiotic for Diverticulitis

    Physician recommended antibiotic for Diverticulitis taken for 10-14 days. Antibiotic not specified for study.

06

What researchers measure

Primary outcomes

  1. Global Symptom Score (GSS) at Week 12, Primary Efficacy Population

    GSS - Abdominal Pain \& Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse).

    Time frame: 12 Weeks

Secondary outcomes

  1. Percentage of Responders at Week 12 - ITT Population

    Responder - patient whose GSS scores for all symptoms were either 0 or 1 GSS - Abdominal Pain \& Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse).

    Time frame: 12 Weeks

  2. Percentage of Responders at Week 52 - ITT Population

    Responder - patient whose GSS scores for all symptoms were either 0 or 1 GSS - Abdominal Pain \& Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse).

    Time frame: 52 Weeks

  3. Change in GSS From Baseline to Week 12 - ITT Population

    GSS - Abdominal Pain \& Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse).

    Time frame: Baseline to Week 12

  4. Change in GSS From Baseline to Week 52 - ITT Population

    GSS - Abdominal Pain \& Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse).

    Time frame: Baseline to Week 52

  5. Withdrawal Due to Surgery for Diverticulitis, Percentage, ITT Population, Week 12

    Time frame: 12 Weeks

  6. Recurrent Diverticulitis, Percentage, ITT Population, Week 12

    At least one report of recurrent diverticulitis since the last visit (prior to the Week 12 visit).

    Time frame: 12 Weeks

  7. Recurrent Diverticulitis, Percentage, ITT Population, Week 52

    At least one report of recurrent diverticulitis since the last visit (prior to the Week 52 visit).

    Time frame: 52 Weeks

07

Results

Posted Jun 21, 2011

Participant flow

First patient screened 6 Dec 2007

Treatment Period (12 Weeks)
Participant flow — Treatment Period (12 Weeks)
MilestonePlaceboMesalamineMesalamine & Probiotic
Started414036
Completed293227
Not completed1289
Withdrew: Adverse event351
Withdrew: Physician decision300
Withdrew: Lost to follow-up102
Withdrew: Recurrent diverticulitis,surgery require120
Withdrew: Protocol violation002
Withdrew: Withdrawal by subject414
Non-Treatment Phase (9 Months)
Participant flow — Non-Treatment Phase (9 Months)
MilestonePlaceboMesalamineMesalamine & Probiotic
Started293227
Completed222724
Not completed753
Withdrew: Lost to follow-up120
Withdrew: Relapse211
Withdrew: Withdrawal by subject422

Outcome measures

PrimaryGlobal Symptom Score (GSS) at Week 12, Primary Efficacy Population

GSS - Abdominal Pain \& Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse).

Time frame:
12 Weeks
Reported as:
Mean · Scores on a Scale
Global Symptom Score (GSS) at Week 12, Primary Efficacy Population
Scores on a ScalePlaceboMesalamineMesalamine & Probiotic
Global Symptom Score (GSS) at Week 12, Primary Efficacy Population7.3 ± 1.304.4 ± 1.075.9 ± 1.16
Statistical analysis
  • Placebo vs Mesalamine · ANCOVA · p = 0.3781 · Mean difference vs. placebo: -3.0Fixed effects for treatment, number of diverticulitis attacks and baseline value as covariate.
  • Placebo vs Mesalamine & Probiotic · ANCOVA · p = 0.6285 · Mean difference vs. placebo: -1.4Fixed effects for treatment, number of diverticulitis attacks and baseline value as covariate.
  • Mesalamine vs Mesalamine & Probiotic · ANCOVA · p = 0.4365 · Mean difference vs. asacol: 1.6Fixed effects for treatment, number of diverticulitis attacks and baseline value as covariate.
SecondaryPercentage of Responders at Week 12 - ITT Population

Responder - patient whose GSS scores for all symptoms were either 0 or 1 GSS - Abdominal Pain \& Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse).

Time frame:
12 Weeks
Reported as:
Number · Percentage of Participants
Percentage of Responders at Week 12 - ITT Population
Percentage of ParticipantsPlaceboMesalamineMesalamine & Probiotic
Percentage of Responders at Week 12 - ITT Population41.462.548.1
Statistical analysis
  • Placebo vs Mesalamine · Cochran-Mantel-Haenszel · p = 0.0576 · Difference vs. placebo: 21.1Stratified by number of diverticulitis attacks.
  • Placebo vs Mesalamine & Probiotic · Cochran-Mantel-Haenszel · p = 0.3248 · Difference vs. placebo: 6.8Stratified by number of diverticulitis attacks.
  • Mesalamine vs Mesalamine & Probiotic · Cochran-Mantel-Haenszel · p = 0.8596 · Difference vs. mesalamine: -14.4Stratified by number of diverticulitis attacks.
SecondaryPercentage of Responders at Week 52 - ITT Population

Responder - patient whose GSS scores for all symptoms were either 0 or 1 GSS - Abdominal Pain \& Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse).

Time frame:
52 Weeks
Reported as:
Number · Percentage of Participants
Percentage of Responders at Week 52 - ITT Population
Percentage of ParticipantsPlaceboMesalamineMesalamine & Probiotic
Percentage of Responders at Week 52 - ITT Population50.066.729.2
Statistical analysis
  • Placebo vs Mesalamine · Cochran-Mantel-Haenszel · p = 0.1266 · Difference vs. placebo: 16.7Stratified by number of diverticulitis attacks.
  • Placebo vs Mesalamine & Probiotic · Cochran-Mantel-Haenszel · p = 0.9288 · Difference vs. placebo: -20.8Stratified by number of diverticulitis attacks.
  • Mesalamine vs Mesalamine & Probiotic · Cochran-Mantel-Haenszel · p = 0.9962 · Difference vs. placebo: -37.5Stratified by number of diverticulitis attacks.
SecondaryChange in GSS From Baseline to Week 12 - ITT Population

GSS - Abdominal Pain \& Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse).

Time frame:
Baseline to Week 12
Reported as:
Mean · Scores on a Scale
Change in GSS From Baseline to Week 12 - ITT Population
Scores on a ScalePlaceboMesalamineMesalamine & Probiotic
Change in GSS From Baseline to Week 12 - ITT Population-16.14 ± 2.082-17.63 ± 1.825-16.11 ± 2.110
Statistical analysis
  • Placebo vs Mesalamine · ANOVA · p = 0.3082 · Ls mean difference vs. placebo: -1.400Fixed effects for treatment and number of diverticulitis attacks.
  • Placebo vs Mesalamine & Probiotic · ANOVA · p = 0.5113 · Ls mean difference vs. placebo: 0.083Fixed effects for treatment and number of diverticulitis attacks.
  • Mesalamine vs Mesalamine & Probiotic · ANOVA · p = 0.6988 · Ls mean difference vs. mesalamine: 1.483Fixed effects for treatment and number of diverticulitis attacks.
SecondaryChange in GSS From Baseline to Week 52 - ITT Population

GSS - Abdominal Pain \& Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse).

Time frame:
Baseline to Week 52
Reported as:
Mean · Scores on a Scale
Change in GSS From Baseline to Week 52 - ITT Population
Scores on a ScalePlaceboMesalamineMesalamine & Probiotic
Change in GSS From Baseline to Week 52 - ITT Population-16.82 ± 2.527-17.30 ± 2.040-16.00 ± 1.931
Statistical analysis
  • Placebo vs Mesalamine · ANOVA · p = 0.4448 · Ls mean difference vs. placebo: -0.428Fixed effects for treatment and number of diverticulitis attacks.
  • Placebo vs Mesalamine & Probiotic · ANOVA · p = 0.6029 · Ls mean difference vs. placebo: 0.825Fixed effects for treatment and number of diverticulitis attacks.
  • Mesalamine vs Mesalamine & Probiotic · ANOVA · p = 0.6615 · Ls mean difference vs. mesalamine: 1.253Fixed effects for treatment and number of diverticulitis attacks.
SecondaryWithdrawal Due to Surgery for Diverticulitis, Percentage, ITT Population, Week 12
Time frame:
12 Weeks
Reported as:
Number · Percentage of Participants
Withdrawal Due to Surgery for Diverticulitis, Percentage, ITT Population, Week 12
Percentage of ParticipantsPlaceboMesalamineMesalamine & Probiotic
Withdrawal Due to Surgery for Diverticulitis, Percentage, ITT Population, Week 122.45.00.0
Statistical analysis
  • Placebo vs Mesalamine · Cochran-Mantel-Haenszel · p = 0.7165 · Difference vs. placebo: 2.6Stratified by number of diverticulitis attacks.
  • Placebo vs Mesalamine & Probiotic · Cochran-Mantel-Haenszel · p = 0.1708 · Difference vs. placebo: -2.4Stratified by number of diverticulitis attacks.
  • Mesalamine vs Mesalamine & Probiotic · Cochran-Mantel-Haenszel · p = 0.1039 · Difference vs. mesalamine: -5.0Stratified by number of diverticulitis attacks.
SecondaryRecurrent Diverticulitis, Percentage, ITT Population, Week 12

At least one report of recurrent diverticulitis since the last visit (prior to the Week 12 visit).

Time frame:
12 Weeks
Reported as:
Number · Percentage of Participants
Recurrent Diverticulitis, Percentage, ITT Population, Week 12
Percentage of ParticipantsPlaceboMesalamineMesalamine & Probiotic
Recurrent Diverticulitis, Percentage, ITT Population, Week 1220.012.511.8
Statistical analysis
  • Placebo vs Mesalamine · Cochran-Mantel-Haenszel · p = 0.1907 · Difference vs. placebo: -7.5Stratified by number of diverticulitis attacks.
  • Placebo vs Mesalamine & Probiotic · Cochran-Mantel-Haenszel · p = 0.1730 · Difference vs. placebo: -8.2Stratified by number of diverticulitis attacks.
  • Mesalamine vs Mesalamine & Probiotic · Cochran-Mantel-Haenszel · p = 0.4613 · Difference vs. mesalamine: -0.7Stratified by number of diverticulitis attacks.
SecondaryRecurrent Diverticulitis, Percentage, ITT Population, Week 52

At least one report of recurrent diverticulitis since the last visit (prior to the Week 52 visit).

Time frame:
52 Weeks
Reported as:
Number · Percentage of Participants
Recurrent Diverticulitis, Percentage, ITT Population, Week 52
Percentage of ParticipantsPlaceboMesalamineMesalamine & Probiotic
Recurrent Diverticulitis, Percentage, ITT Population, Week 5231.028.137.0
Statistical analysis
  • Placebo vs Mesalamine · Cochran-Mantel-Haenszel · p = 0.3983 · Difference vs. placebo: -2.9Stratified by number of diverticulitis attacks.
  • Placebo vs Mesalamine & Probiotic · Cochran-Mantel-Haenszel · p = 0.6721 · Difference vs. placebo: 6.0Stratified by number of diverticulitis attacks.
  • Mesalamine vs Mesalamine & Probiotic · Cochran-Mantel-Haenszel · p = 0.7703 · Difference vs. mesalamine: 8.9Stratified by number of diverticulitis attacks.

Adverse events

Collected over 6 Dec 2007 thru 1 Mar 2010. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—6/41 (14.6%)32/41 (78%)
Mesalamine—5/40 (12.5%)37/40 (92.5%)
Mesalamine & Probiotic—0/36 (0%)26/36 (72.2%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventPlaceboMesalamineMesalamine & Probiotic
DiverticulitisInfections and infestations2/410/400/36
Atrioventricular BlockCardiac disorders1/290/320/27
Benign Ovarian TumourNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/290/320/27
Colon OperationSurgical and medical procedures1/290/320/27
GastritisGastrointestinal disorders1/290/320/27
SyncopeNervous system disorders1/290/320/27
Arterial Thrombosis LimbVascular disorders0/291/320/27
BronchopneumoniaInfections and infestations0/291/320/27
Tendon RuptureInjury, poisoning and procedural complications0/291/320/27
Vascular PseudoaneurysmInjury, poisoning and procedural complications0/291/320/27
Most frequent other events
Showing 10 of 89
Most frequent other events
EventPlaceboMesalamineMesalamine & Probiotic
Abdominal PainGastrointestinal disorders1/4112/404/36
ConstipationGastrointestinal disorders5/413/403/36
PyrexiaGeneral disorders3/291/322/27
DiarrhoeaGastrointestinal disorders2/414/403/36
NauseaGastrointestinal disorders4/411/401/36
PainGeneral disorders0/410/403/36
HaematocheziaGastrointestinal disorders0/413/400/36
Upper Respiratory Tract InfectionInfections and infestations1/291/322/27
Abdominal Pain LowerGastrointestinal disorders3/410/402/36
Back PainMusculoskeletal and connective tissue disorders2/411/402/36

Baseline characteristics

Age, Customized
Age, Customized(Participants)PlaceboMesalamineMesalamine & ProbioticTotal
< 65 years31282584
>= 65 years10121133
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboMesalamineMesalamine & ProbioticTotal
Female19231961
Male22171756
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboMesalamineMesalamine & ProbioticTotal
Hispanic or Latino42410
Not Hispanic or Latino373832107
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboMesalamineMesalamine & ProbioticTotal
Caucasian393933111
Black2024
Asian (Oriental)0011
Multi-racial0101
Region of Enrollment
Region of Enrollment(participants)PlaceboMesalamineMesalamine & ProbioticTotal
United States414036117
08

Study locations

36 sites
  • Research Site
    Tucson, Arizona, United States
  • Research Facility
    Los Angeles, California, United States
  • Research Site
    Merced, California, United States
  • Research Site
    Oakland, California, United States
  • Research Facility
    Orange, California, United States
  • Research Site
    Palm Springs, California, United States
  • Research Site
    Pasadena, California, United States
  • Research Site
    Lafayette, Colorado, United States
  • Research Site
    Littleton, Colorado, United States
  • Research Site
    Boynton Beach, Florida, United States
  • Research Site
    Jacksonsville, Florida, United States
  • Research Site
    Jacksonville, Florida, United States
  • Research Site
    Winter Park, Florida, United States
  • Research Facility
    Zephyrhills, Florida, United States
  • Research Site
    Pratt, Kansas, United States
  • Research Site
    Monroe, Louisiana, United States
  • Research Site
    Shreveport, Louisiana, United States
  • Research Site
    Chesterfield, Michigan, United States
  • Research Site
    Tupelo, Mississippi, United States
  • Research Site
    Mexico, Missouri, United States
  • Research Facility
    Cedar Knolls, New Jersey, United States
  • Research Site
    Great Neck, New York, United States
  • Research Site
    Lake Success, New York, United States
  • Research Site
    Setauket, New York, United States
  • Research Site
    Asheville, North Carolina, United States
  • Research Site
    Greenville, North Carolina, United States
  • Research Facility
    Harrisburg, North Carolina, United States
  • Research Site
    Morganton, North Carolina, United States
  • Research Site
    Wilmington, North Carolina, United States
  • Research Site
    Winston-Salem, North Carolina, United States
  • Research Site
    Cincinnati, Ohio, United States
  • Research Site
    Cranston, Rhode Island, United States
  • Research Site
    Longview, Texas, United States
  • Research Site
    Odessa, Texas, United States
  • Research Site
    Chesapeake, Virginia, United States
  • Research Facility
    Monroe, Wisconsin, United States
09

References and documents

Publications

  • Stollman N, Magowan S, Shanahan F, Quigley EM; DIVA Investigator Group. A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. J Clin Gastroenterol. 2013 Aug;47(7):621-9. doi: 10.1097/MCG.0b013e31828003f6. PubMed 23426454 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2011, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2007
First posted
Nov 6, 2007
Start
Nov 2007
Primary completionActual
Mar 2010
CompletionActual
Mar 2010
Results first posted
Jun 21, 2011
Last update
Apr 22, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00554099
Lead sponsor
Warner Chilcott
Responsible party
Sponsor
First posted
Nov 6, 2007
Start date
Nov 2007
Primary completion
Mar 2010
Completion
Mar 2010
Results posted
Jun 21, 2011
Last update
Apr 22, 2013

Study contacts

Ana Balske, MD, PhD
study director · Procter and Gamble

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mesalamine · Probiotic

Start the discussion